Literature DB >> 33796826

Relationship Between Proliferative Breast Lesions and Breast Cancer Risk Factors.

Osman Toktaş1, Sadi Elasan2, Ümit Haluk İliklerden1, Remzi Erten3, Ali Rıza Karayil1, Abdulselam Özdemir1, Fırat Aslan1, Serhat Binici1, İbrahim Özalp1, Enes Şentürk1.   

Abstract

OBJECTIVE: The prognosis of breast cancer (BC) is determined directly based on the stage of disease at the time of diagnosis. Proliferative breast lesions (PBLs) are an important risk factor for BC development. The risk of developing BC varies according to the presence of extent of proliferation in the breast lesions. We aimed to investigate the effect of BC risk factors on the PBLs in this study.
MATERIALS AND METHODS: Patients who visited the surgical clinic of the university during the past 6 years who presented with PBLs with or without atypia by fine/core needle aspiration biopsy were included in this study. The relationship between PBLs and BC risk factors such as the age, mass size, Body Mass index (BMI), smoking, sports activity, BC family history, the use of hormone replacement therapy, number of pregnancies, and the duration of breastfeeding were compared.
RESULTS: A total of 74 (96.1%) of all patients were women and three were men. The median age of the patients was 38 (range: 19-74) years; the cut-off value of age was 35.5 years. The mean age of patients with PBL-with atypia (PBL-WA) was higher (p=0.005) in the malignant group based on the final pathology and radiological imaging features (for both, p<0.001). The mean size of the mass was large at 2.53±1.33 (1-6) cm; and the cut-off value of the tumor size was 2.5 cm. The mean size was greater in the PBL-WA patients (p=0.171) in the malignant group based on the final pathology and radiological characteristic (respectively, p=0.004 and p=0.016). The mean BMI was 26.8±4.4 kg/m2 (18.8-35.1) and the cut-off value was 25.4 kg/m2. BMI was greater in the PBL-WA group and in the malignant group based on the final pathology (respectively, p=0.002 and p=0.001). Smoking was positive in 66.2% (n=51) of the patients, and it was high in the PBL-WA patients (p=0.001). The percentage of patients with no sports activity was 63.6% (n=49), while it was 20.8% (n=16) for those with once a week sports activity and 15.6% (n=12) for those with twice a week activity. There was family history of BC in 16.9% (n=13) of all patients. The number of positive cases of family history of BC was greater in the malignant group (p=0.001). Hormone replacement therapy was recorded in 11.7% (n=9) of the patients. The mean numbers of pregnancies (2.1±2.4) and breastfeeding duration (32.5±37.4 months) were low in the benign groups due to the relatively lower average age of the patients.
CONCLUSION: Based on our analysis, age is an extremely important aspect for assessing PBLs. The age of the patient was statistically significantly greater in the patients with malignant lesions in all groups. The factors lesion size, BMI, smoking habit, and BC family history were also more frequent in the malignant groups. The rate of sports activity was lower in the malignant groups. Thus, it is necessary to evaluate patients individually when evaluating PBLs. It is recommended to evaluate PBLs together with BC risk factors for the better understanding. ©Copyright 2021 by Turkish Federation of Breast Diseases Associations.

Entities:  

Keywords:  Breast cancer; benign breast disease; proliferative breast lesion with atypia or without atypia

Year:  2020        PMID: 33796826      PMCID: PMC8006792          DOI: 10.4274/ejbh.2020.5713

Source DB:  PubMed          Journal:  Eur J Breast Health


  25 in total

1.  Oral contraceptives and the risk of breast cancer.

Authors:  Polly A Marchbanks; Jill A McDonald; Hoyt G Wilson; Suzanne G Folger; Michele G Mandel; Janet R Daling; Leslie Bernstein; Kathleen E Malone; Giske Ursin; Brian L Strom; Sandra A Norman; Phyllis A Wingo; Ronald T Burkman; Jesse A Berlin; Michael S Simon; Robert Spirtas; Linda K Weiss
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

2.  Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.

Authors:  Amy C Degnim; William D Dupont; Derek C Radisky; Robert A Vierkant; Ryan D Frank; Marlene H Frost; Stacey J Winham; Melinda E Sanders; Jeffrey R Smith; David L Page; Tanya L Hoskin; Celine M Vachon; Karthik Ghosh; Tina J Hieken; Lori A Denison; Jodi M Carter; Lynn C Hartmann; Daniel W Visscher
Journal:  Cancer       Date:  2016-06-28       Impact factor: 6.860

3.  Adult weight change and risk of postmenopausal breast cancer.

Authors:  A Heather Eliassen; Graham A Colditz; Bernard Rosner; Walter C Willett; Susan E Hankinson
Journal:  JAMA       Date:  2006-07-12       Impact factor: 56.272

4.  A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States).

Authors:  S E Hankinson; G A Colditz; J E Manson; W C Willett; D J Hunter; M J Stampfer; F E Speizer
Journal:  Cancer Causes Control       Date:  1997-01       Impact factor: 2.506

5.  A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer.

Authors:  Geoffrey C Kabat; Joan G Jones; Neal Olson; Abdissa Negassa; Catherine Duggan; Mindy Ginsberg; Rita A Kandel; Andrew G Glass; Thomas E Rohan
Journal:  Cancer Causes Control       Date:  2010-01-19       Impact factor: 2.506

6.  A prospective study of smoking and risk of breast cancer in young adult women.

Authors:  Wael K Al-Delaimy; Eunyoung Cho; Wendy Y Chen; Graham Colditz; Walter C Willet
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-03       Impact factor: 4.254

Review 7.  Minireview: Obesity and breast cancer: the estrogen connection.

Authors:  Margot P Cleary; Michael E Grossmann
Journal:  Endocrinology       Date:  2009-04-16       Impact factor: 4.736

8.  Stratification of breast cancer risk in women with atypia: a Mayo cohort study.

Authors:  Amy C Degnim; Daniel W Visscher; Hal K Berman; Marlene H Frost; Thomas A Sellers; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; Piet C de Groen; Wilma L Lingle; Karthik Ghosh; Lois Penheiter; Thea Tlsty; L Joseph Melton; Carol A Reynolds; Lynn C Hartmann
Journal:  J Clin Oncol       Date:  2007-06-11       Impact factor: 44.544

9.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

10.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.